Abstract
Interleukin (IL)-23 is a member of the IL-12 family of cytokines that, as the other members of this family, is secreted by monocytes, macrophages, and dendritic cells (DC) upon recognition of bacterial, viral, and fungal components. IL-23 is critical during immunity against acute infections, and it is also involved in the development of autoimmune diseases. Although immunoregulatory effects of IL-23 on mouse natural killer (NK) cells have been described, the effect of IL-23 on human NK cells remains ill-defined. In this study, we observed that monocytes stimulated with LPS secreted IL-23 and that blockade of this cytokine during monocyte and NK cell coculture led to a diminished production of IFN-γ by NK cells. Accordingly, rIL-23-induced NK cell activation and stimulated IFN-γ production by CD56bright NK cells. This effect involved MEK1/MEK2, JNK, PI3K, mammalian target of rapamycin, and NF-κB, but not STAT-1, STAT-3, nor p38 MAPK pathways. Moreover, while NK cell-mediated cytotoxicity remained unaltered, antibody-dependent cellular cytotoxicity (ADCC) was enhanced after IL-23 stimulation. In addition, IL-23 displayed a synergistic effect with IL-18 for IFN-γ production by both CD56bright and CD56dim NK cells, and this effect was due to a priming effect of IL-23 for IL-18 responsiveness. Furthermore, NK cells pre-stimulated with IL-18 promoted an increase in CD86 expression and IL-12 secretion by DC treated with LPS, and IL-23 potentiated these effects. Moreover, IL-23-driven enhancement of NK cell “helper” function was dependent on NK cell-derived IFN-γ. Therefore, our results suggest that IL-23 may trigger NK cell-mediated “helper” effects on adaptive immunity, shaping T cell responses during different pathological situations through the regulation of DC maturation.
Introduction
Natural killer (NK) cells constitute a subgroup of type 1 innate lymphoid cells that are key players during immunity against intracellular pathogens and tumors due to their cytotoxicity and the secretion of IFN-γ and other pro-inflammatory cytokines (1–3). In humans, they are subdivided into two subpopulations based on the relative expression of CD56 and CD16 (4). Almost 90% of peripheral blood NK cells are CD56dimCD16+ (CD56dim), and although they can produce cytokines upon activation (5, 6), their principal effector function is the cytotoxic activity displayed against susceptible target cells (7, 8). The rest of NK cells in blood are CD56brightCD16dim/− (CD56bright), which are mainly producers of cytokines (4, 8) and are more abundant in secondary lymphoid organs where they exert immunoregulatory functions (9). NK cells become activated after direct recognition of infected or tumor cells through a vast array of activating receptors (10) and by cytokines such as interleukin (IL)-12, IL-15, and IL-18 (11, 12) or their combination with PAMPs (13). Monocytes, macrophages, and dendritic cells (DC) are the major producers of these cytokines during their crosstalk with NK cells (14–16). As a result of this bidirectional crosstalk, in some circumstances, activated NK cells kill immature DC, favoring the selection of immunogenic DC necessary for an appropriate immune response (17, 18). In addition, DC stimulate NK cell activation while NK cells enhance macrophage activation and promote DC maturation, and NKp30 and cytokines have been involved in both events (19, 20). Therefore, NK cells skew the adaptive immune response toward a T helper (Th) 1 and cytotoxic T lymphocyte (CTL) profiles, both essential for an effective antitumor and antiviral immune response (21–24). Also, the crosstalk between DC and NK cells has been involved in the promotion and protection of autoimmune conditions (25–27).
Interleukin-12 plays a major role in NK cell activation in response to pathogens and tumors (28, 29). It belongs to an extended family of cytokines that share cytokine and receptor subunits and display overlapping functions (30, 31). Recently, we demonstrated that IL-27, another member of IL-12 family, induces human NK cell-mediated cytotoxicity, IFN-γ production, and potentiates antibody-dependent NK cell-mediated cytotoxicity (ADCC) (32). In addition, IL-27 synergizes with IL-18 for the stimulation of NK cell effector functions (32–34). IL-23 is another member of the IL-12 family composed by the IL-12p40 and p19 subunits that signals through a heterodimeric receptor composed by the IL-12Rβ1 and the IL-23R chains (35, 36). Similarly to IL-12 and IL-27, IL-23 is secreted by monocytes, macrophages, and DC in response to bacterial, viral, and fungal components (37, 38). IL-23 increases IFN-γ production by human CD4+ T cells (35, 39), and it is also involved in survival, expansion, and activation of Th17 cells (31). Data obtained in mice indicate that IL-23 can both inhibit (40) and activate (41, 42) NK cell responses. However, IL-23 effects on human NK cells remain ill-defined. Therefore, in this work, we explored the role of IL-23 on human NK cell effector functions and demonstrated that it stimulated IFN-γ secretion by CD56bright, but not CD56dim cells, primed NK cells for IL-18-driven IFN-γ production, and that NK cells co-stimulated with IL-23 and IL-18 enhanced IL-12 secretion and CD86 expression on DC in an IFN-γ-dependent manner.
Materials and Methods
Antibodies and Reagents
Human rIL-2 and rIL-15 (PeproTech), rIL-18 (MBL International), rIL-23 (eBioscience), rGM-CSF (Sigma), and rIL-4 (R&D) were used. Cells were incubated with fluorochrome-coupled mAb against the following human molecules: CD25 (BC96), CD1a (HI149), NKp46 (9E2), NKp30 (P30-15), NKp44 (P44-8), NKp80 (5D12), IFN-γ (4S.B3), T-bet (4B10), CD178 (FasL, NOK-1), CD14 (HCD14), CD83 (HB15e), CD16 (3G8), unlabeled anti-IFN-γ (NIB42), fluorochrome-labeled, and unlabeled isotype-matched controls (IC) from Biolegend; CD226 (DNAM-1, DX11), CD69 (FN50) and CD154 (CD40L, TRAP1) from BD Pharmingen; CD56 (N901) from Beckman Coulter; NKG2C (134591), TRAIL (71908), TIGIT (741182), CD85j (ILT2, 292305), IL-18Rα (H44), IL-18Rβ (132029), and IL-23R (218213) from R&D; CD3 (UCHT-1), HLA-DR (L243), and CD86 (IT2.2) from Tonbo; Eomes (WD1928) from eBioscience; unlabeled anti-IL-23p19 (B-Z23) from Abcam. The following reagents were used at the indicated concentrations: the inhibitor of c-Jun N-terminal kinase (JNK) SP600125 (20 µM, Calbiochem); the Janus kinase 2 (Jak2) inhibitor AG490 (25 µM, Calbiochem); the p38 MAP kinase inhibitor SB202190 (10 µM, Calbiochem); the inhibitor of phosphoinositide 3-kinase (PI3K) Ly294002 (2 µM, Sigma); the inhibitor of MEK1/MEK2 kinases (MAPKs) U0126 (5 µM, Sigma); the inhibitor of cytokine-induced IκBα phosphorylation BAY11-7082 (1 µM, Sigma); the inhibitor of the mammalian target of rapamycin (mTOR) rapamycin (5 nM, Sigma); the inhibitor of STAT1 Fludarabine (0.1 µg/ml, Fludara® Schering). LPS (E. coli 0111:B4 strain, Sigma) was used at 0.1 or 1 µg/ml. The dose of each pharmacological inhibitor used in the experiments was established in previous work (13, 32) and did not affect NK cell viability. Rituximab (RTX, Roche) and normal human polyclonal IgG (IgG2500, Purissimus, Argentina) were used at 10 µg/ml.
Monocytes, DC, and NK Cells
Buffy coats from healthy volunteers were provided by the Blood Bank of the “Carlos Durand” Hospital or by the “Complejo Médico Churruca-Visca” (Buenos Aires, Argentina). Monocytes (CD14+ cells) were isolated by MACS (Miltenyi); NK cells were isolated using RosetteSep (StemCell) and Ficoll-Paque™ Plus (GE Life Sciences) centrifugation. Purity of isolated cells was always above 90%, as assessed by flow cytometry (FC; CD14+ cells or CD3−CD56+). Monocytes (1 × 105) were incubated for 24 h with LPS (1 µg/ml), then, NK cells (1 × 105) were added for another 24 h in the presence of an IC mAb or a neutralizing anti-IL-23p19 mAb (10 µg/ml) and IFN-γ was evaluated in the supernatants. Also, cell culture supernatants of monocytes incubated for 48 h with LPS were used for analysis of IL-23 production. Monocytes were cultured for 6 days with GM-CSF and IL-4 to obtain immature DC (iDC) characterized as CD1a+MHC-IIlowCD83−/lowCD86−/low. DCs (1 × 105) were cultured for 18 h with previously stimulated and washed NK cells (1 × 105) plus LPS (0.1 µg/ml) in the absence or in the presence of an IC mAb or a neutralizing anti-IFN-γ mAb (10 µg/ml). Cells were cultured in RPMI 1640 (Gibco) supplemented with 10% inactivated fetal bovine serum (Gibco), sodium pyruvate, glutamine, and gentamicin (Sigma). Cell culture supernatants were collected and used for analysis of IL-12 production and cells were used to assess CD86 expression. Also, NK cells (1 × 106/ml) were cultured for 24 h or 5 days in the presence of IL-15 (4 ng/ml) and in the absence or in the presence of IL-18 (10 ng/ml), IL-23 (10 ng/ml), or their combination. In some experiments, NK cells stimulated with IL-23 were thereafter stimulated with IL-2 (8 ng/ml) for 24 h. For dose–response experiments, IL-23 was also used at 1 ng/ml. Cells were used for phenotypic analysis, cytokine production, proliferation, and cell death evaluation. For cytotoxicity assessment and NK cell “helper” function evaluation, NK cells (2 × 106/ml) were incubated overnight. To investigate the signaling pathways involved in the IFN-γ response, NK cells were incubated with pharmacologic inhibitors for 45–60 min and then stimulated with the different cytokines for another 23 h. For priming experiments, NK cells (1 × 106/ml) were cultured overnight in the absence or in the presence of IL-18 or IL-23, extensively washed and further cultured (1 × 106/ml) for 24 h in the absence or in the presence of IL-23 or IL-18, as indicated in the figure. Studies have been approved by the institutional review committee and informed consent of participating subjects was obtained.
NK Cell Proliferation
Natural killer cells cultured for 5 days as described, were pulsed with 1 μCi/well of methyl-3H-thymidine (3H-Thy; New England Nuclear Life Science) during the last 18 h of cell culture, harvested on glass-fiber filters, and incorporated radioactivity was measured in a liquid scintillation counter. Results are expressed as mean counts per minute (cpm) of triplicate wells ± SEM.
Flow Cytometry and Cell Sorting
Expression of cell surface receptors on NK cells or DC was analyzed by FC as previously described (43). Expression of IFN-γ, Eomes and T-bet was analyzed by intracellular FC using Cytofix/Cytoperm (BD). For assessment of IFN-γ production, cells were cultured in the presence of Golgi-Plug® and Golgi-Stop® reagents during the last 4 h. For CD40L analysis, cells were cultured in the presence of the specific mAb and Golgi-Stop® during the last 6 h, as described (44) with slight modifications. Human CD40L-transfected fibroblasts were used as positive controls. Samples were acquired in a FACSCanto II-plus flow cytometer (BD) or MACSQuant Analyzer 10 (Miltenyi Biotec). Data were analyzed using FlowJo software (Tree Star). Results were expressed as percentage of positive cells or MFI. For cell sorting, NK cells were isolated using RosetteSep (StemCell), stained with mAb against CD56 and CD16 and then CD56bright (CD56highCD16−/low) and CD56dim (CD56dimCD16high) NK cells were sorted in a FACSAria II-plus cell sorter (BD Biosciences).
ELISA
Secretion of IFN-γ (Biolegend), IL-12 (ELISA MAX Standard kit, Biolegend), and IL-23 (DuoSet, R&D) was analyzed by ELISA as described (13).
Cytokine Bead Array
Secretion of IL-4, IL-10, IL-17, IL-6, TNF, and IFN-γ by cytokine-stimulated NK cells was analyzed by the CBA (BD) as indicated by the manufacturer.
NK Cell-Mediated Cytotoxicity
Natural killer cells were cultured overnight with IL-15 in the absence or in the presence of IL-18, IL-23, or the combination of both, washed, and co-cultured for 5 h with CFSE-labeled Raji (Burkitt’s lymphoma, ATCC) at different E:T ratios. Cells were thereafter labeled with 7-AAD and analyzed by FC. Percentage of cytotoxicity was calculated as 100 × percentage of CFSE+7-AAD+ cells/percentage of CFSE+ cells. Percentage of spontaneous dead cells (without effector NK cells) was always below 5%. For ADCC, CFSE-labeled Raji cells previously incubated with RTX or normal human IgG for 2 h were used as target at a 1:1 E:T ratio.
Statistical Analysis
Paired t-test or Wilcoxon matched paired test (when data did not pass the normality test) were used when two experimental groups were compared. A one-way ANOVA test with Bonferroni post hoc test was used when three or more experimental groups were compared. A one-way ANOVA test with Dunnett’s post hoc test was used in pharmacologic inhibition experiments. When data did not pass normality test, Friedman test with Dunn’s post hoc test was used instead. A two-way ANOVA with repeated measures and Bonferroni post hoc test was used for IFN-γ production by sorted NK cells and by IL-23 plus IL-18-stimulated NK cells, for cytotoxicity and for DC-NK cell co-cultures in the presence of neutralizing mAb experiments. The interaction effect in the 2 × 2 factorial ANOVA was performed for the definition of synergism, and P values for it were reported in the legends of the figures (45). Data were analyzed using GraphPad Prism 6.0 software.
Results
Monocytes Produce IL-23 That Stimulates NK Cell IFN-γ Production
To assess whether IL-23 participates in the crosstalk between monocytes and NK cells, we first evaluated the capacity of monocytes to produce this cytokine. Accordingly, we observed that they secreted IL-23 upon stimulation with LPS (Figure 1A). Moreover, IL-23 blockade led to a significant reduction in the amounts of IFN-γ secreted by NK cells during their coculture with LPS-stimulated monocytes (Figure 1B). Next, we stimulated isolated NK cells with recombinant human IL-23 and confirmed that this cytokine-induced IFN-γ production not only by resting (Figure 1C) but also by NK cells previously activated with a combination of IL-12, IL-15, and IL-18 (data not shown). Conversely, IL-23 did not promote the secretion of IL-4, IL-10, IL-17, IL-6, and TNF by NK cells, assessed by Cytokine Bead Array (CBA) and FC (data not shown). Pharmacologic inhibition revealed that MEK1/MEK2, JNK, PI3K, mTOR, and NF-κB but not p38 MAPK, Jak2 (Figure 1D), or STAT1 (data not shown) were involved in the IL-23-driven IFN-γ response. Besides, IL-23 did not affect NK cell-mediated cytotoxicity (Figure 1E). Accordingly, this cytokine did not affect the expression of the activating receptors CD335 (NKp46), CD336 (NKp44), CD337 (NKp30), NKp80 (KLRF1), CD226 (DNAM-1), NKG2C nor the expression of TRAIL and CD178/FasL (data not shown). Therapeutic efficacy of humanized monoclonal antibodies directed against tumor cell surface-expressed molecules relies partially on ADCC. We observed that RTX-coated Raji cells were susceptible to NK cell-mediated cytotoxicity and that IL-23 further increased such susceptibility in a statistically significant manner (Figure 1F). Of note, IL-23 did not alter the expression levels of CD16 on NK cells (data not shown).
Figure 1
In addition, IL-23 induced a higher percentage of CD69+ (Figures 2A,B) and CD25+ (Figures 2C,D) NK cells indicating that this cytokine promoted NK cell activation. Furthermore, NK cells first incubated with IL-23 secreted higher amounts of IFN-γ than non-stimulated NK cells when they were re-stimulated with IL-2, suggesting that the effect of IL-23 on CD25 expression had functional consequences (Figure 2E).
Figure 2
Next, we analyzed intracellular IFN-γ production by CD56bright and CD56dim NK cells in response to IL-23. Although we did not detect differences in the percentage of IFN-γ+ NK cells in these subpopulations, we observed higher amounts of IFN-γ expression in CD56bright but not in CD56dim NK cells stimulated with IL-23 compared to unstimulated cells (data not shown). To confirm this result, we FACS-sorted CD56bright and CD56dim NK cells and observed a statistically significant increase in IFN-γ secretion by CD56bright but not CD56dim NK cells upon IL-23 stimulation (Figure 3A). Accordingly, CD56bright NK cells expressed higher amounts of IL-23 receptor (IL-23R) than CD56dim NK cells (Figure 3B).
Figure 3
IL-23 Primes NK Cells for IL-18-Induced IFN-γ Production
Previous reports demonstrated that IL-12 (46) and IL-27 (32) display a cooperative effect with IL-18 on the activation of NK cell effector functions. Therefore, we investigated whether IL-23 cooperates with IL-18 for NK cell stimulation. First, we performed a dose–response curve and observed a statistically significant increase in the secretion of IFN-γ when NK cells were stimulated with two different concentrations of IL-23 plus IL-18 in comparison with IL-18 alone (Figure 4A). We confirmed the existence of a cooperative effect with a larger number of donors and using resting (Figure 4B) and activated NK cells (data not shown). Statistical analysis based on testing the interaction effect in a two-way ANOVA (45) demonstrated the existence of a synergistic effect between IL-23 and IL-18. Moreover, in opposition to the effect of IL-23 alone, we detected that this synergistic effect was noticeable both on CD56bright (Figures 4C,D) and on CD56dim (Figures 4E,F) NK cells. As IL-23 only exerted an effect on IFN-γ production by CD56dim NK cells when combined with IL-18, we explored whether such combination also affected NK cell-mediated cytotoxicity. However, even in combination with IL-18, IL-23 did not regulate NK cell-mediated cytotoxic activity (Figure 4G).
Figure 4
To further interrogate the cause of the synergistic effect induced by IL-23 and IL-18 on IFN-γ production by NK cells, we performed sequential stimulations. We observed that pre-stimulation of NK cells with IL-18 and subsequent stimulation with IL-23 induced a minor increase in IFN-γ secretion. Conversely, pre-stimulation of NK cells with IL-23 and subsequent stimulation with IL-18 induced a significant increased IFN-γ secretion compared to NK cells not pretreated with IL-23 (Figure 5A). Therefore, the synergistic effect was due to a priming of NK cells by IL-23 for IL-18 responsiveness.
Figure 5
To explore the mechanisms involved in the priming effect, we addressed the expression of T-bet, Eomes, IL-18Rα, and IL-18Rβ in NK cells stimulated with IL-23. While T-bet and IL-18Rβ expression remain unchanged, IL-23 induced a decrease in Eomes expression (data not shown) and a statistically significant upregulation of the expression of IL-18Rα in CD56bright but not CD56dim NK cells (Figure 5B). Therefore, upregulated expression of IL-18Rα induced by IL-23 may explain the increased responsiveness of NK cells to IL-18.
As IL-23 promotes the proliferation of memory T cells and the increased levels of IFN-γ observed could also be a result of an increase in the total number of NK cells, we investigated the effect of IL-23 on NK cells proliferation. Surprisingly, IL-23 exerted a statistically significant inhibition of NK cell proliferation triggered by IL-15 and IL-15 plus IL-18 (Figure 5C) without affecting NK cell viability (data not shown).
IL-23 Cooperates with IL-18 in the Promotion of DC Activation
As NK cell–DC crosstalk shapes adaptive immunity, we examined whether NK cells co-stimulated with IL-23 and IL-18 affect DC maturation. NK cells were stimulated overnight in the absence or in the presence of IL-23, IL-18, or both, and then cocultured with DC pulsed with LPS. We observed a statistically significant increase in CD86 expression (Figures 6A,B) but not in CD83 or HLA-DR expression (data not shown) on DC when NK cells were pre-stimulated with IL-23 and IL-18 compared to DC cocultured with NK cells stimulated with each cytokine alone. Moreover, we observed an increased secretion of IL-12 (Figure 6C) by DC when NK cells were pre-stimulated with both cytokines. To investigate the underlying mechanisms, we stimulated NK cells with IL-23, IL-18, or IL-23 and IL-18, and we evaluated the expression of CD40L, DNAM-1, NKG2D, NKG2C, NKp30, NKp46, TIGIT, and ILT2 on NK cells. However, we did not observe differences that could suggest the involvement of any of these receptors in the potentiation of DC activation when they were cocultured with NK cells pre-stimulated with IL-23 and IL-18 (data not shown). Conversely, neutralization of IFN-γ during the cocultures of DC and NK cells pre-stimulated with the combination of the cytokines abrogated both effects, CD86 expression (Figures 6D,E), and IL-12 secretion (Figure 6F). Therefore, IL-23 in concert with IL-18 promotes NK cell activation that drives DC maturation mainly by IFN-γ produced by NK cells.
Figure 6
Discussion
Interleukin-23 has been involved in immunity against tumors (29, 47) and acute infections (30, 31) but also contributes to tumor promotion and growth (40, 48) and the development of autoimmune diseases, mainly through the induction of a Th17 response (30, 49). These opposing functions may depend on the context and/or on the immune cells on which IL-23 exerts its effects. In mice, IL-23 triggers pro- (40) and antitumoral (41, 42) effects on NK cells. However, little is known about its effect on human NK cells (50). In this study, we demonstrated that monocytes incubated with LPS secrete IL-23 that stimulates IFN-γ secretion mostly by CD56bright NK cells, which could be due to the observation that CD56bright NK cells express higher amounts of IL-23R than CD56dim NK cells. Of note, we used low doses of IL-15 as survival factor and to prime NK cells as it has been shown that resting NK cells require at least two signals for efficient IFN-γ secretion (9, 12, 21, 51, 52). Also, as the secretion of cytokines is usually restricted to the synaptic cleft between DC and NK cells (53, 54), the concentration of cytokines in sera might be quite different from the concentration that NK cells sense. Nevertheless, the concentration of IL-23 used in our experiments is within the range of values detected in sera from patients with different physiopathological conditions (55, 56). Besides, they are similar to the concentration of IL-23 detected in supernatants from monocyte-derived DCs of multiple sclerosis patients stimulated with LPS (57) or produced by macrophages and DC stimulated with pathogens or TLR ligands (37, 58, 59).
In addition, in this study, we observed that IL-23-driven IFN-γ production requires functional MEK1/MEK2, JNK, PI3K, mTOR, and NF-κB, but not STAT-1, STAT-3 (a downstream mediator of Jak2), nor p38 MAPK. All these signaling pathways have previously been implicated in NK cell effector functions (13, 32, 60, 61).
Interleukin-4, IL-10, IL-17, and TNF were shown to be secreted by NK cells under certain conditions and different immune cells stimulated with IL-23 produce IL-17, IL-6, and TNF (30, 62–65). However, IL-23 did not affect their secretion by NK cells. Nevertheless, we observed a raise in the percentage of CD69+ and CD25+ NK cells upon stimulation with IL-23, confirming that this cytokine activates NK cells. Moreover, IL-23 potentiated ADCC (mediated through CD16) but not NK cell-mediated cytotoxicity through other NK cell activating receptors, suggesting that this cytokine may act as a co-stimulus not only for IFN-γ production but also for CD16-mediated cytotoxicity. Interestingly, potentiation of ADCC is a biological effect that IL-23 shares with IL-12 and IL-27 (32, 60), which suggests that these cytokines of the IL-12 family of cytokines might be suitable candidates as adjuvant therapy during immunotherapy with humanized mAb.
Myeloid cells can produce IL-18 upon recognition of tumors and pathogens, which in combination with other stimuli such as IL-12 or IL-27 activates NK cells (32, 34, 46). Here, we demonstrated that IL-23, like the other members of the same family of cytokines, displays a synergistic effect with IL-18 for NK cell-mediated IFN-γ production by both CD56bright and CD56dim cells. Interestingly, this effect is due to a priming of IL-23 for IL-18-responsiveness and not to a proliferative effect on NK cells or to changes in their viability. On the contrary, we observed an IL-23-driven inhibition of NK cell proliferation similar to what we have already seen for another member of the IL-12 family of cytokines, IL-27 (32). The upregulation of IL-18Rα expression on CD56bright NK cells observed in our experiments might be responsible for the priming effect that led to an increased responsiveness of NK cells to IL-18 for IFN-γ production.
Remarkably, CD56dim NK cells only produced IFN-γ in response to the simultaneous stimulation with both cytokines but not in response to IL-23 alone, as did CD56bright NK cells. However, NK cell-mediated cytotoxicity was not affected when NK cells were stimulated with IL-23 or with IL-23 and IL-18. Therefore, IL-23 might display a predominant immunoregulatory but not a cytotoxicity-inducing effect on NK cells, which is in contrast with the effect of other members of the same family of cytokines such as IL-12 and IL-27 (28, 29, 32). These results further support the notion that both effector functions are differentially regulated in NK cells (13, 66). Also, the lack of effect of IL-23 on NK cell cytotoxicity could be due to the fact that CD56dim NK cells express less IL-23R than CD56bright NK cells. Nonetheless, IL-23 induced IFN-γ secretion by CD56dim NK cells in combination with IL-18 and enhanced ADCC, which indicates that it may act as co-stimulatory cytokine when acting in concert with another primary stimulus for NK cells.
Immature DC are mainly localized in peripheral tissues and migrate to secondary lymphoid organs upon maturation induced by PAMP or tumors to induce an adaptive immune response. NK cells activated upon target cell recognition or by cytokines such as IL-2 or IL-12 induce CD86 expression and IL-12 production by DCs (15, 21, 24, 67). Therefore, we hypothesized that IL-23 and IL-18 secreted by myeloid cells during the onset of an immune response may activate NK cells that in turn might affect maturation of DC that already sensed PAMP, which in turn may affect T cell priming. To mimic this situation in vitro with human cells, we used LPS during DC–NK cell cocultures to activate DC. We observed that NK cells pre-stimulated with IL-18 induced heightened secretion of IL-12 and increased expression of CD86 on DC activated with LPS, and that this effect is further potentiated by IL-23. This effect could be related to the “helper” function acquired by NK cells exposed to IL-18 that leads to the stimulation of IL-12 production by DC activated through CD40 and the development of a Th1 response (51). In our experimental setting, we did not observe differences in the expression of CD40L as other authors did (68, 69), or other activating or inhibitory receptors on NK cells that could suggest the involvement of surface molecules in the potentiation of DC activation. Conversely, we observed that IL-23 enhanced IL-18-driven NK cell “helper” function mainly through IFN-γ production.
Our results show that the effects of IL-23 on NK cells are mostly immunoregulatory and that this cytokine cooperates with IL-18, which suggest that IL-23 may actually functions as a co-stimulatory cytokine that principally potentiates the effect of IL-18 in NK cells. These observations also explain the pro- or antitumoral effects described for IL-23 on NK cells (29, 40–42, 47, 48), which may critically depend on the composition of the tumor microenvironment, in particular, the presence of other cytokines that regulate NK cell effector functions.
Overall, we conclude that IL-23 produced by activated myeloid cells induces NK cell activation and IFN-γ secretion, which enhances IL-18-driven NK cell “helper” activity that fosters DC maturation and IL-12 secretion. Therefore, our results unravel the stimulatory functions of IL-23 on NK cells, and their possible impact on the Th1- and CTL-mediated adaptive immune response against tumors and pathogens.
Statements
Ethics statement
Studies have been approved by the institutional review committee from IBYME.
Author contributions
AZ participated in the design of the study, performed and analyzed the experiments, prepared the figures, and wrote and corrected the manuscript. SN, XI, RS, FS, NT, JS, CD, and MF assisted in performing experiments and analyzing results. NZ designed the study, analyzed the experiments, and corrected the manuscript. All authors reviewed the results and approved the final version of the manuscript.
Funding
This work was supported by grants from the National Agency for Promotion of Science and Technology from Argentina (ANPCYT), the National Research Council of Argentina (CONICET), and the University of Buenos Aires (UBA), all to NZ. We also thank to Fundación Williams and Fundación René Barón for providing financial assistance (donations) to our laboratory. SN, NT, FS, and JS are fellows of CONICET. CD, MF, and NZ are members of the Researcher Career of CONICET.
Acknowledgments
We thank the workers of the Transfusion Medicine of the Hospital “Churruca-Visca” and of the Hemotherapy Service of the “Hospital Durand” (Buenos Aires, Argentina), for providing buffy coats. Also, we thank Dr. Gabriel A. Rabinovich from the Laboratory of Immunopathology of IBYME for his continuous support and for generously providing unlimited access to the Flow Cytometer and Cell Sorter.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
ArtisDSpitsH. The biology of innate lymphoid cells. Nature (2015) 517:293–301.10.1038/nature14189
2
LodoenMBLanierLL. Natural killer cells as an initial defense against pathogens. Curr Opin Immunol (2006) 18:391–8.10.1016/j.coi.2006.05.002
3
VivierETomaselloEBaratinMWalzerTUgoliniS. Functions of natural killer cells. Nat Immunol (2008) 9:503–10.10.1038/ni1582
4
CooperMAFehnigerTACaligiuriMA. The biology of human natural killer-cell subsets. Trends Immunol (2001) 22:633–40.10.1016/S1471-4906(01)02060-9
5
FauriatCLongEOLjunggrenHGBrycesonYT. Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood (2010) 115:2167–76.10.1182/blood-2009-08-238469
6
De MariaABozzanoFCantoniCMorettaL. Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16+ NK cells as rapid producers of abundant IFN-gamma on activation. Proc Natl Acad Sci U S A (2011) 108:728–32.10.1073/pnas.1012356108
7
Di SantoJP. Functionally distinct NK-cell subsets: developmental origins and biological implications. Eur J Immunol (2008) 38:2948–51.10.1002/eji.200838830
8
CaligiuriMA. Human natural killer cells. Blood (2008) 112:461–9.10.1182/blood-2007-09-077438
9
FerlazzoGPackMThomasDPaludanCSchmidDStrowigTet alDistinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc Natl Acad Sci U S A (2004) 101:16606–11.10.1073/pnas.0407522101
10
LanierLL. NK cell recognition. Annu Rev Immunol (2005) 23:225–74.10.1146/annurev.immunol.23.021704.115526
11
ZwirnerNWDomaicaCI. Cytokine regulation of natural killer cell effector functions. Biofactors (2010) 36:274–88.10.1002/biof.107
12
FehnigerTAShahMHTurnerMJVanDeusenJBWhitmanSPCooperMAet alDifferential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol (1999) 162:4511–20.
13
GirartMVFuertesMBDomaicaCIRossiLEZwirnerNW. Engagement of TLR3, TLR7, and NKG2D regulate IFN-gamma secretion but not NKG2D-mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12. J Immunol (2007) 179:3472–9.10.4049/jimmunol.179.6.3472
14
MichelTHentgesFZimmerJ. Consequences of the crosstalk between monocytes/macrophages and natural killer cells. Front Immunol (2012) 3:403.10.3389/fimmu.2012.00403
15
WalzerTDalodMRobbinsSHZitvogelLVivierE. Natural-killer cells and dendritic cells: “l’union fait la force”. Blood (2005) 106:2252–8.10.1182/blood-2005-03-1154
16
ChijiokeOMunzC. Dendritic cell derived cytokines in human natural killer cell differentiation and activation. Front Immunol (2013) 4:365.10.3389/fimmu.2013.00365
17
WilsonJLHefflerLCCharoJScheyniusABejaranoMTLjunggrenHG. Targeting of human dendritic cells by autologous NK cells. J Immunol (1999) 163:6365–70.
18
FerlazzoGMorettaL. Dendritic cell editing by natural killer cells. Crit Rev Oncog (2014) 19:67–75.10.1615/CritRevOncog.2014010827
19
FerlazzoGTsangMLMorettaLMelioliGSteinmanRMMünzC. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med (2002) 195:343–51.10.1084/jem.20011149
20
VitaleMDella ChiesaMCarlomagnoSPendeDAricòMMorettaLet alNK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor. Blood (2005) 106:566–71.10.1182/blood-2004-10-4035
21
MailliardRBSonYIRedlingerRCoatesPTGiermaszAMorelPAet alDendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. J Immunol (2003) 171:2366–73.10.4049/jimmunol.171.5.2366
22
Martin-FontechaAThomsenLLBrettSGerardCLippMLanzavecchiaAet alInduced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol (2004) 5:1260–5.10.1038/ni1138
23
BoehmUKlampTGrootMHowardJC. Cellular responses to interferon-gamma. Annu Rev Immunol (1997) 15:749–95.10.1146/annurev.immunol.15.1.749
24
GerosaFBaldani-GuerraBNisiiCMarchesiniVCarraGTrinchieriG. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med (2002) 195:327–33.10.1084/jem.20010938
25
TerrazzanoGSicaMGianfraniCMazzarellaGMauranoFDe GiulioBet alGliadin regulates the NK-dendritic cell cross-talk by HLA-E surface stabilization. J Immunol (2007) 179:372–81.10.4049/jimmunol.179.1.372
26
ChongWPvan PanhuysNChenJSilverPBJittayasothornYMattapallilMJet alNK-DC crosstalk controls the autopathogenic Th17 response through an innate IFN-gamma-IL-27 axis. J Exp Med (2015) 212:1739–52.10.1084/jem.20141678
27
GianchecchiEDelfinoDVFierabracciA. NK cells in autoimmune diseases: linking innate and adaptive immune responses. Autoimmun Rev (2017).10.1016/j.autrev.2017.11.018
28
Scharton-KerstenTAfonsoLCWysockaMTrinchieriGScottP. IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis. J Immunol (1995) 154:5320–30.
29
XuMMizoguchiIMorishimaNChibaYMizuguchiJYoshimotoT. Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27. Clin Dev Immunol (2010) 2010:832454.10.1155/2010/832454
30
HunterCA. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol (2005) 5:521–31.10.1038/nri1648
31
KasteleinRAHunterCACuaDJ. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol (2007) 25:221–42.10.1146/annurev.immunol.22.012703.104758
32
ZiblatADomaicaCISpallanzaniRGIraolagoitiaXLRossiLEAvilaDEet alIL-27 stimulates human NK-cell effector functions and primes NK cells for IL-18 responsiveness. Eur J Immunol (2015) 45:192–202.10.1002/eji.201444699
33
ZwirnerNWZiblatA. Regulation of NK cell activation and effector functions by the IL-12 family of cytokines: the case of IL-27. Front Immunol (2017) 8:25.10.3389/fimmu.2017.00025
34
LauwerysBRRenauldJCHoussiauFA. Synergistic proliferation and activation of natural killer cells by interleukin 12 and interleukin 18. Cytokine (1999) 11:822–30.10.1006/cyto.1999.0501
35
OppmannBLesleyRBlomBTimansJCXuYHunteBet alNovel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity (2000) 13(5):715–25.10.1016/S1074-7613(00)00070-4
36
ParhamCChiricaMTimansJVaisbergETravisMCheungJet alA receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol (2002) 168:5699–708.10.4049/jimmunol.168.11.5699
37
GerosaFBaldani-GuerraBLyakhLABatoniGEsinSWinkler-PickettRTet alDifferential regulation of interleukin 12 and interleukin 23 production in human dendritic cells. J Exp Med (2008) 205:1447–61.10.1084/jem.20071450
38
SieveANMeeksKDLeeSBergRE. A novel immunoregulatory function for IL-23: inhibition of IL-12-dependent IFN-gamma production. Eur J Immunol (2010) 40:2236–47.10.1002/eji.200939759
39
LankfordCSFruchtDM. A unique role for IL-23 in promoting cellular immunity. J Leukoc Biol (2003) 73:49–56.10.1189/jlb.0602326
40
TengMWAndrewsDMMcLaughlinNvon ScheidtBNgiowSFMollerAet alIL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis. Proc Natl Acad Sci U S A (2010) 107:8328–33.10.1073/pnas.1003251107
41
HuJYuanXBelladonnaMLOngJMWachsmann-HogiuSFarkasDLet alInduction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells. Cancer Res (2006) 66:8887–96.10.1158/0008-5472.CAN-05-3448
42
KaigaTSatoMKanedaHIwakuraYTakayamaTTaharaH. Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12. J Immunol (2007) 178:7571–80.10.4049/jimmunol.178.12.7571
43
RossiLEAvilaDESpallanzaniRGZiblatAFuertesMBLapyckyjLet alHistone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression. J Leukoc Biol (2012) 91:321–31.10.1189/jlb.0711339
44
ChattopadhyayPKYuJRoedererM. Live-cell assay to detect antigen-specific CD4+ T-cell responses by CD154 expression. Nat Protoc (2006) 1:1–6.10.1038/nprot.2006.1
45
SlinkerBK. The statistics of synergism. J Mol Cell Cardiol (1998) 30:723–31.10.1006/jmcc.1998.0655
46
ChaixJTessmerMSHoebeKFuseriNRyffelBDalodMet alPriming of NK cells by IL-18. J Immunol (2008) 181:1627–31.10.4049/jimmunol.181.3.1627
47
LoCHLeeSCWuPYPanWYSuJChengCWet alAntitumor and antimetastatic activity of IL-23. J Immunol (2003) 171:600–7.10.4049/jimmunol.171.2.600
48
LangowskiJLZhangXWuLMattsonJDChenTSmithKet alIL-23 promotes tumour incidence and growth. Nature (2006) 442:461–5.10.1038/nature04808
49
LangrishCLChenYBlumenscheinWMMattsonJBashamBSedgwickJDet alIL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med (2005) 201:233–40.10.1084/jem.20041257
50
van de WeteringDde PausRAvan DisselJTvan de VosseE. IL-23 modulates CD56+/CD3- NK cell and CD56+/CD3+ NK-like T cell function differentially from IL-12. Int Immunol (2009) 21:145–53.10.1093/intimm/dxn132
51
MailliardRBAlberSMShenHWatkinsSCKirkwoodJMHerbermanRBet alIL-18-induced CD83+CCR7+ NK helper cells. J Exp Med (2005) 202:941–53.10.1084/jem.20050128
52
LucasMSchachterleWOberleKAichelePDiefenbachA. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity (2007) 26:503–17.10.1016/j.immuni.2007.03.006
53
SeminoCAngeliniGPoggiARubartelliA. NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1. Blood (2005) 106:60916.10.1182/blood-2004-10-3906
54
BorgCJalilALaderachDMaruyamaKWakasugiHCharrierSet alNK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. Blood (2004) 104:3267–75.10.1182/blood-2004-01-0380
55
LiuCZhangYZhanJZhaoYWanQPengHet alInterleukin-23A is associated with tumor growth in Helicobacter-pylori-related human gastric cancer. Cancer Cell Int (2014) 14:104.10.1186/s12935-014-0104-x
56
NogueiraEHamourSSawantDHendersonSMansfieldNChaveleKMet alSerum IL-17 and IL-23 levels and autoantigen-specific Th17 cells are elevated in patients with ANCA-associated vasculitis. Nephrol Dial Transplant (2010) 25:2209–17.10.1093/ndt/gfp783
57
Vaknin-DembinskyABalashovKWeinerHL. IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production. J Immunol (2006) 176:7768–74.10.4049/jimmunol.176.12.7768
58
RosesREXuSXuMKoldovskyUKoskiGCzernieckiBJ. Differential production of IL-23 and IL-12 by myeloid-derived dendritic cells in response to TLR agonists. J Immunol (2008) 181:5120–7.10.4049/jimmunol.181.7.5120
59
VerreckFAde BoerTLangenbergDMHoeveMAKramerMVaisbergEet alHuman IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc Natl Acad Sci U S A (2004) 101:4560–5.10.1073/pnas.0400983101
60
KondadasulaSVRodaJMPariharRYuJLehmanACaligiuriMAet alColocalization of the IL-12 receptor and FcgammaRIIIa to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon-gamma. Blood (2008) 111:4173–83.10.1182/blood-2007-01-068908
61
NandagopalNAliAKKomalAKLeeSH. The critical role of IL-15-PI3K-mTOR pathway in natural killer cell effector functions. Front Immunol (2014) 5:187.10.3389/fimmu.2014.00187
62
HaoJSShanBE. Immune enhancement and anti-tumour activity of IL-23. Cancer Immunol Immunother (2006) 55:1426–31.10.1007/s00262-006-0171-5
63
PandyaADAl-JaderiZHoglundRAHolmoyTHarboHFNorgauerJet alIdentification of human NK17/NK1 cells. PLoS One (2011) 6:e26780.10.1371/journal.pone.0026780
64
Perona-WrightGMohrsKSzabaFMKummerLWMadanRKarpCLet alSystemic but not local infections elicit immunosuppressive IL-10 production by natural killer cells. Cell Host Microbe (2009) 6:503–12.10.1016/j.chom.2009.11.003
65
CarboneTNasorriFPenninoDDonnarummaMGarcovichSEyerichKet alCD56 highCD16- NK cell involvement in cutaneous lichen planus. Eur J Dermatol (2010) 20:724–30.10.1684/ejd.2010.1096
66
KubotaALianRHLohwasserSSalcedoMTakeiF. IFN-gamma production and cytotoxicity of IL-2-activated murine NK cells are differentially regulated by MHC class I molecules. J Immunol (1999) 163:6488–93.
67
AgauguéSMarcenaroEFerrantiBMorettaLMorettaA. Human natural killer cells exposed to IL-2, IL-12, IL-18, or IL-4 differently modulate priming of naive T cells by monocyte-derived dendritic cells. Blood (2008) 112:1776–83.10.1182/blood-2008-02-135871
68
CarboneETerrazzanoGRuggieroGZanziDOttaianoAManzoCet alRecognition of autologous dendritic cells by human NK cells. Eur J Immunol (1999) 29:4022–9.10.1002/(SICI)1521-4141(199912)29:12<4022::AID-IMMU4022>3.0.CO;2-O
69
CarboneERuggieroGTerrazzanoGPalombaCManzoCFontanaSet alA new mechanism of NK cell cytotoxicity activation: the CD40-CD40 ligand interaction. J Exp Med (1997) 185:2053–60.10.1084/jem.185.12.2053
Summary
Keywords
natural killer cells, interleukin-23, interleukin-18, IFN-γ, dendritic cells
Citation
Ziblat A, Nuñez SY, Raffo Iraolagoitia XL, Spallanzani RG, Torres NI, Sierra JM, Secchiari F, Domaica CI, Fuertes MB and Zwirner NW (2018) Interleukin (IL)-23 Stimulates IFN-γ Secretion by CD56bright Natural Killer Cells and Enhances IL-18-Driven Dendritic Cells Activation. Front. Immunol. 8:1959. doi: 10.3389/fimmu.2017.01959
Received
17 August 2017
Accepted
19 December 2017
Published
17 January 2018
Volume
8 - 2017
Edited by
Miguel López-Botet, Institut Hospital del Mar d’Investigacions Mèdiques, Spain
Reviewed by
Francisco Borrego, BioCruces Health research Institute, Spain; Ennio Carbone, Magna Græcia University, Italy; Hugh Thomson Reyburn, Consejo Superior de Investigaciones Científicas (CSIC), Spain
Updates
Copyright
© 2018 Ziblat, Nuñez, Raffo Iraolagoitia, Spallanzani, Torres, Sierra, Secchiari, Domaica, Fuertes and Zwirner.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Norberto W. Zwirner, nzwirner@ibyme.conicet.gov.ar
†Present address: Ximena Lucía Raffo Iraolagoitia, Cancer Research UK Beatson Institute, Bearsden, Glasgow, United Kingdom; Raúl German Spallanzani, Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA, United States
ORCID Id: 0000-0001-7098-359X.
‡These authors have contributed equally to this work.
Specialty section: This article was submitted to NK and Innate Lymphoid Cell Biology, a section of the journal Frontiers in Immunology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.